China Biotech Services Holdings (HKSE:08037) Change In Receivables : HK$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is China Biotech Services Holdings Change In Receivables?

China Biotech Services Holdings's change in receivables for the quarter that ended in Dec. 2024 was HK$0.00 Mil. It means China Biotech Services Holdings's Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

China Biotech Services Holdings's change in receivables for the fiscal year that ended in Dec. 2024 was HK$-33.74 Mil. It means China Biotech Services Holdings's Accounts Receivable increased by HK$33.74 Mil from Dec. 2023 to Dec. 2024 .

China Biotech Services Holdings's Accounts Receivable for the quarter that ended in Dec. 2024 was HK$7.03 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. China Biotech Services Holdings's liquidation value for the three months ended in Dec. 2024 was HK$-261.39 Mil.

China Biotech Services Holdings Change In Receivables Historical Data

The historical data trend for China Biotech Services Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biotech Services Holdings Change In Receivables Chart

China Biotech Services Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-22.23

-64.85

-656.42

726.42

-33.74

China Biotech Services Holdings Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

China Biotech Services Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

China Biotech Services Holdings (HKSE:08037) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

China Biotech Services Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	7.033	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, China Biotech Services Holdings's accounts receivable are only considered to be worth 75% of book value:

China Biotech Services Holdings's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	18.913	-	287.567	+	0.75 * 7.033	+	0.5 * 3.971
=	-261.39

China Biotech Services Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of China Biotech Services Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

China Biotech Services Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

255-257 Gloucester Roaad, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG

Website

http://www.cbshhk.com

China Biotech Services Holdings Ltd is an investment holding company. It operates through six segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Securities, Insurance brokerage, BNCT and Others. It derives prime revenue from the Medical and health related services segment which involves the provision of medical laboratory testing and health check services. The group has a business presence in Hong Kong and the PRC, of which key revenue is generated from Hong Kong.

Executives

Guoyuan International Holdings Limited	2201 Interest of corporation controlled by you
Guoyuan Securities Co., Ltd.	2201 Interest of corporation controlled by you
Guoyuan Securities Investment (hong Kong) Limited	2101 Beneficial owner
Genius Earn Limited	2201 Interest of corporation controlled by you
Genius Lead Limited	2101 Beneficial owner
Liu Xiaolin	2101 Beneficial owner
Richlane Ventures Limited	2101 Beneficial owner
Ko Chun Shun, Johnson	2201 Interest of corporation controlled by you

China Biotech Services Holdings Headlines

No Headlines